Topic
Pertuzumab
About: Pertuzumab is a research topic. Over the lifetime, 1453 publications have been published within this topic receiving 73219 citations. The topic is also known as: 2C4 Antibody & MOAB 2C4.
Papers published on a yearly basis
Papers
More filters
TL;DR: The antitumor activity with the significant reduction in the risk of progression or death, as reflected upon the increase of 6.1 months in median progression-free survival, indicates that pertuzumab may provide an avenue for achieving additional benefit for patients with HER2(+).
15 citations
TL;DR: Crofelemer is not systemically absorbed, has relatively few side effects, and presents a targeted approach at preventing CID in patients receiving pertuzumab‐based therapy, which is a phase II, randomized, open‐label trial that aims to recruit 46 patients.
14 citations
TL;DR: In vitro and in vivo experiments showed Her2(Per)-S-Fab had potent cytotoxicity against Her2-positive tumor cells, suggesting this bispecific antibody may provide an alternative to treat Her1-positive cancer patients.
Abstract: Human epidermal growth factor receptor 2 (HER2) is frequently overexpressed and activated in metastatic breast cancers. Monoclonal antibodies targeting Her2, such as trastuzumab and pertuzumab, have become important targeted therapies for patients with HER2-positive breast cancer. Both trastuzumab and pertuzumab can reduce Her2 positive tumor burden by inhibiting Her2 signaling and inducing ADCC activities (antibody dependent cell-mediated cytotoxicity). In this study, we have generated a bispecific antibody, Her2(Per)-S-Fab, by linking the pertuzumab Fab to an anti-CD16 single domain antibody. The Her2(Per)-S-Fab can be expressed and purified efficiently from Escherichia coli. In vitro and in vivo experiments showed Her2(Per)-S-Fab had potent cytotoxicity against Her2-positive tumor cells. Thus, Her2(Per)-S-Fab may provide an alternative to treat Her2-positive cancer patients.
14 citations
TL;DR: A unique case of a patient with metastatic hormone receptorepositive, ERBB2-not amplified breast cancer, with a S310F activating mutation who responded to treatment with trastuzumab is presented, highlighting the increasing importance of genomic testing patients with nonamplified ER BB2 breast cancers.
14 citations
TL;DR: The APHINITY trial as mentioned in this paper showed that pertuzumab (P) added to T plus chemotherapy significantly improved invasive disease-free survival (IDFS) leading to a new standard of care for high-risk patients.
14 citations